Literature DB >> 21449629

Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.

April D Miller1, Amanda M Ball, P Brandon Bookstaver, Emily K Dornblaser, Charles L Bennett.   

Abstract

Antimicrobials are the most frequently implicated class of drugs in drug-induced seizure, with β-lactams being the class of antimicrobials most often implicated. The seizure-inducing potential of the carbapenem subclass may be directly related to their β-lactam ring structure. Data on individual carbapenems and seizure activity are scarce. To evaluate the available evidence on the association between carbapenem agents and seizure activity, we conducted a literature search of the MEDLINE (1966-May 2010), EMBASE (1974-May 2010), and International Pharmaceutical Abstracts (1970-May 2010) databases. Reference citations from the retrieved articles were also reviewed. Mechanistically, seizure propensity of the β-lactams is related to their binding to γ-aminobutyric acid (GABA) receptors. There are numerous reports of seizure activity associated with imipenem-cilastatin, with seizure rates ranging from 3-33%. For meropenem, doripenem, and ertapenem, the seizure rate for each agent is reported as less than 1%. However, as their use increases and expands into new patient populations, the rate of seizures with these agents may increase. High-dose therapy, especially in patients with renal dysfunction, preexisting central nervous system abnormalities, or a seizure history increases the likelihood of seizure activity. Although specific studies have not been conducted, data indicate that carbapenem-associated seizure is best managed with benzodiazepines, followed by other agents that enhance GABA transmission. Due to the drug interaction between carbapenems and valproic acid, resulting in clinically significant declines in valproic acid serum concentrations, the combination should be avoided whenever possible. Clinicians should be vigilant regarding the possibility of carbapenem-induced seizures when selecting and dosing antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21449629     DOI: 10.1592/phco.31.4.408

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  16 in total

1.  Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics.

Authors:  Cristina Gervasoni; Dario Cattaneo; Felicia Stefania Falvella; Paola Vitiello; Stefania Cheli; Laura Milazzo; Emilio Clementi; Agostino Riva
Journal:  Eur J Clin Pharmacol       Date:  2013-04-25       Impact factor: 2.953

Review 2.  Neurologic Complications of Commonly Used Drugs in the Hospital Setting.

Authors:  Elliot T Dawson; Sara E Hocker
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

3.  Ertapenem-associated neurotoxicity in the spinal cord injury (SCI) population: A case series.

Authors:  Ursula C Patel; Mallory A Fowler
Journal:  J Spinal Cord Med       Date:  2017-09-06       Impact factor: 1.985

Review 4.  Clinical Pharmacology of Antibiotics.

Authors:  Rachel F Eyler; Kristina Shvets
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-12       Impact factor: 8.237

5.  Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment.

Authors:  Haijing Yang; Min Zhang; Yuancheng Chen; Hong Ren; Hong Zhang; Chen Yu; Jianda Lu; Li You; Jicheng Yu; Hong Liang; Cuilan Xiao; Zishuang He; Jufang Wu; Jun Xue; Jing Zhang
Journal:  Eur J Clin Pharmacol       Date:  2022-04-06       Impact factor: 2.953

6.  Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis.

Authors:  Beatriz Fernández-Rubio; Rafael Luque-Márquez; María-Victoria Gil-Navarro
Journal:  Daru       Date:  2022-01-13       Impact factor: 4.088

7.  Safety of high-dose doripenem in adult patients with cystic fibrosis.

Authors:  Seth Strawbridge; Michael D Nailor
Journal:  Ther Adv Drug Saf       Date:  2016-04-08

8.  Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.

Authors:  Christoph P Hornik; Amy H Herring; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; John van den Anker; Michael Cohen-Wolkowiez; Reese H Clark; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 3.806

9.  Status Epilepticus and Delirium Associated with Ertapenem in a Very Elderly Patient with Chronic Kidney Disease and Silent Ischaemic Cerebrovascular Disease.

Authors:  Huimin Lin; Samuel T H Chew
Journal:  Drug Saf Case Rep       Date:  2015-12

Review 10.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.